此外，诺华集团和 疟疾药品公司（Medicines for Malaria Venture，在比尔和梅琳达·盖茨基金会的帮助下）将于下个月开始新的临床试验，测试一种叫作KAF156的微粒，它有望成为耐青蒿素疟疾菌株的新治疗手段。
Moreover, Novartis and the Medicines for Malaria Venture (with support from the Bill & Melinda Gates Foundation) are starting a new clinical trial next month to test KAF156, a molecule that could form the basis of a new treatment against artemisinin-resistant malaria strains.